Drug Approval | February 17, 2024
Lupin receives approval from USFDA for Minzoya
Minzoya Tablets are indicated for use by females of reproductive potential to prevent pregnancy
Minzoya Tablets are indicated for use by females of reproductive potential to prevent pregnancy
The Board has elected Dr. Ajit Shetty, who had served as the Company's Interim Chairperson of the Board since December 9, 2023, as Chairperson of the Board, effective February 13, 2024
The CDCCs are strategically positioned in regions identified as high-impact areas
The US FDA's clearance of the trial marks the first global registrational Phase III trial for olverembatinib in patients with CP-CML to be conducted.
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024
Revenue from Operations stood at Rs. 2,607 crore, 25% YoY growth. Domestic revenue at Rs. 2,400 crore, 20% YoY growth and export revenue at Rs. 207 crore, 118% YoY growth
The registered capital of the newly founded company is € 50 million
He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
